Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.

Abstract

AIMS:

To assess differences in diuretic dose requirements in patients treated with sacubitril/valsartan compared with enalapril in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial.

METHODS AND RESULTS:

Overall, 8399 patients with New York Heart Association class II-IV heart failure and reduced LVEF were randomized to sacubitril/valsartan 200 mg bid or enalapril 10 mg twice daily. Loop diuretic doses were assessed at baseline, 6, 12, and 24 months, and furosemide dose equivalents were calculated via multiplication factors (2x for torsemide and 40x for bumetanide). Percentages of participants with reductions or increases in loop diuretic dose were determined. At baseline, 80.8% of participants were taking any diuretics (n = 6290 for loop diuretics, n = 496 for other diuretics); of those, recorded dosage data for loop diuretics were available on 5487 participants. Mean baseline furosemide equivalent doses were 48.2 mg for sacubitril/valsartan and 49.6 mg for enalapril (P = 0.25). Patients treated with sacubitril/valsartan were more likely to reduce diuretic dose and less likely to increase diuretic dose relative to those randomized to enalapril at 6, 12, 24 months post-randomization, with an overall decreased diuretic use of 2.0% (P = 0.02), 4.1% (P < 0.001), and 6.1% (P < 0.001) at 6, 12, and 24 months, respectively, with similar findings in an on-treatment analysis.

CONCLUSION:

Treatment with sacubitril/valsartan was associated with more loop diuretic dose reductions and fewer dose increases compared with enalapril, suggesting that treatment with sacubitril/valsartan may reduce the requirement for loop diuretics relative to enalapril in patients with heart failure with reduced ejection fraction.

• Authors: Orly Vardeny, Brian Claggett, Jessica Kachadourian, Akshay S Desai, Milton Packer, Jean Rouleau, Michael R Zile, Karl Swedberg, Martin Lefkowitz, Victor Shi, John J V McMurray, Scott D Solomon
• Journal: European journal of heart failure (Eur J Heart Fail) Vol. 21 Issue 3 Pg. 337-341 (03 2019) ISSN: 1879-0844 [Electronic] England
• PMID: 30741494 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: © 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Chemical References

• Aminobutyrates
• Angiotensin Receptor Antagonists
• Biphenyl Compounds
• Drug Combinations
• Sodium Potassium Chloride Symporter Inhibitors
• Tetrazoles
• Enalapril
• Furosemide
• Valsartan
• sacubitril and valsartan sodium hydrate drug combination

Topics

• Aged
• Aminobutyrates (administration & dosage, pharmacokinetics)
• Angiotensin Receptor Antagonists (administration & dosage, pharmacokinetics)
• Biological Availability
• Biphenyl Compounds
• Dose-Response Relationship, Drug
• Drug Combinations
• Drug Monitoring (methods, statistics & numerical data)
• Enalapril (administration & dosage, pharmacokinetics)
• Female
• Furosemide (administration & dosage, pharmacokinetics)
• Heart Failure (drug therapy, physiopathology)
• Humans
• Male
• Medication Therapy Management (statistics & numerical data)
• Middle Aged
• Outcome Assessment, Health Care
• Sodium Potassium Chloride Symporter Inhibitors (administration & dosage, pharmacokinetics)
• Stroke Volume
• Tetrazoles (administration & dosage, pharmacokinetics)
• Valsartan